JP2025500508A5 - - Google Patents
Info
- Publication number
- JP2025500508A5 JP2025500508A5 JP2024538418A JP2024538418A JP2025500508A5 JP 2025500508 A5 JP2025500508 A5 JP 2025500508A5 JP 2024538418 A JP2024538418 A JP 2024538418A JP 2024538418 A JP2024538418 A JP 2024538418A JP 2025500508 A5 JP2025500508 A5 JP 2025500508A5
- Authority
- JP
- Japan
- Prior art keywords
- liver
- pharmaceutical composition
- composition according
- cysteine
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210185351A KR20230095666A (ko) | 2021-12-22 | 2021-12-22 | 간 표적 물질 및 이의 용도 |
| KR10-2021-0185351 | 2021-12-22 | ||
| PCT/KR2022/021129 WO2023121370A1 (ko) | 2021-12-22 | 2022-12-22 | 간 표적 물질 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500508A JP2025500508A (ja) | 2025-01-09 |
| JP2025500508A5 true JP2025500508A5 (enExample) | 2026-01-06 |
Family
ID=86903150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538418A Pending JP2025500508A (ja) | 2021-12-22 | 2022-12-22 | 肝臓標的物質及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250121086A1 (enExample) |
| EP (1) | EP4454657A4 (enExample) |
| JP (1) | JP2025500508A (enExample) |
| KR (1) | KR20230095666A (enExample) |
| CN (1) | CN118742317A (enExample) |
| WO (1) | WO2023121370A1 (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| CA2619771C (en) | 2005-08-16 | 2012-05-22 | Hanmi Pharmaceutical Co., Ltd. | A method for the mass production of immunoglobulin fc region deleted initial methionine residues |
| WO2011075393A2 (en) * | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| KR101512702B1 (ko) | 2012-05-23 | 2015-04-16 | 포항공과대학교 산학협력단 | 금속 나노 입자 기반 간 표적 지향 약물 전달체 및 이의 제조방법 |
| ES2602486T3 (es) * | 2012-06-21 | 2017-02-21 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran actividad de receptor de GIP |
| KR102291020B1 (ko) | 2014-12-30 | 2021-08-20 | 한미약품 주식회사 | 안정성이 증가된 글루카곤 유도체 |
| FI3322437T3 (fi) * | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| CN122440793A (zh) * | 2016-06-29 | 2026-07-24 | 韩美药品株式会社 | 胰高血糖素衍生物、其缀合物、包含其的组合物、和其治疗用途 |
| WO2020071865A1 (ko) * | 2018-10-04 | 2020-04-09 | 한미약품 주식회사 | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 |
| MX2021015927A (es) | 2019-06-28 | 2022-04-18 | Hanmi Pharm Ind Co Ltd | Uso terapéutico de agonista trigonal de los receptores de glucagón, glp-1 y gip, o conjugado de los mismos para enfermedades hepáticas. |
| JP7761557B2 (ja) * | 2019-10-04 | 2025-10-28 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 |
| BR112023000515A2 (pt) * | 2020-07-15 | 2023-03-21 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica e seu uso |
-
2021
- 2021-12-22 KR KR1020210185351A patent/KR20230095666A/ko not_active Ceased
-
2022
- 2022-12-22 US US18/723,147 patent/US20250121086A1/en active Pending
- 2022-12-22 CN CN202280092331.5A patent/CN118742317A/zh active Pending
- 2022-12-22 WO PCT/KR2022/021129 patent/WO2023121370A1/ko not_active Ceased
- 2022-12-22 EP EP22912003.5A patent/EP4454657A4/en active Pending
- 2022-12-22 JP JP2024538418A patent/JP2025500508A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10442845B2 (en) | Interferon analogs | |
| US20100093636A1 (en) | Methods of treating inflammation | |
| JP2011530599A5 (enExample) | ||
| JP6158097B2 (ja) | 炎症を抑制するためのペプチド | |
| JP2010518079A5 (enExample) | ||
| CN110248953A (zh) | 新型订书肽及其用途 | |
| JP2023502005A5 (enExample) | ||
| US8003610B2 (en) | Bradykinin B2 receptor antagonist peptide from amphibian skin | |
| JP2024525213A5 (enExample) | ||
| JP2022513626A5 (enExample) | ||
| US8501680B2 (en) | Antagonists against interaction of PF4 and RANTES | |
| CN115698036B (zh) | 新型抗炎肽及其用途 | |
| JP2024534496A5 (enExample) | ||
| CN101671390B (zh) | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 | |
| TW200944236A (en) | G-CSF conjugates modified by water-soluble polymers | |
| JP2023520714A5 (enExample) | ||
| EP3356389A1 (en) | Use of human derived immunosuppressive proteins and peptides as medicaments | |
| RS49733B (sr) | Soli bpc peptida sa organo- zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena | |
| TWI911432B (zh) | 含有多種多套胜肽的重組蛋白質、含有該重組蛋白質的醫藥組成物以及該重組蛋白質之製備方法 | |
| JP2022513438A5 (enExample) | ||
| JP2022515721A5 (enExample) | ||
| US20260028397A1 (en) | Methods of treating ankylosing spondylitis | |
| CN108822190B (zh) | 多肽及其药物组合物和用途 | |
| JP2002510496A (ja) | 細胞傷害性ｔ細胞を誘導するための医薬 | |
| JP2014198711A (ja) | Ｃｔ阻害４価ペプチドおよびコレラ治療薬 |